Sustainable access to effective antibiotics
In a new position paper, IFPMA explores some of the challenges in ensuring access to safe and quality-assured antibiotics and propose a set of policy changes for consideration.
Read more
IFPMA 2014 interview Series: Andrew Jenner’s take on ‘Value of innovation’
In this video, Andrew Jenner, IFPMA’s Executive Director, Corporate Strategy & Legal Affairs, gives the pharmaceutical industry perspective on innovation. Despite the growing scientific, intellectual property and regulatory challenges of the past decades, over 340 new drugs have been introduced since 2002 to treat different chronic and non-chronic diseases. This can be considered as a...
Read moreIFPMA 2014 interview series on ‘The R&D challenges in tackling Ebola’
This IFPMA video interview with Ripley Ballou, who’s in charge of GlaxoSmithKline’s (GSK’s) Ebola vaccine program in Rixensart, Belgium, was recorded soon after Ebola scientists and representatives from companies and regulatory bodies met at the World Health Organization’s (WHO’s) headquarters in Geneva, Switzerland, 4-5 September, to discuss how to speed up clinical development of vaccines,...
Read more2nd global Biopharma CEO / top execs virtual press briefing – COVID-19
IFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D. The briefing was an opportunity to hear directly from the decision-makers.
Read moreBiotech, developing and developed countries vaccine manufacturers COVID-19 press briefing
The press briefing will take stock of the contribution and difficulties of scaling up COVID-19 vaccines production, and the short and longer term challenges that need to be addressed.
Read more
Biotech, developing and developed countries vaccine manufacturers COVID-19 press briefing
This press briefing took stock of the progress achieved in developing and scaling up COVID-19 vaccines production, and addressed the challenges that need to be tackled.
Read more